{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224080","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2026-05-14T20:17:07+00:00","discovered_at":"2026-05-14T20:19:00.239560+00:00","generated_at":"2026-05-14T20:47:18.977542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RenovoRx Q1 revenue $563K (+136% QoQ); net loss $3.5M; reaffirms FY revenue guidance $3-4M","bullets":["Revenue $563,000, up 136% from Q4 2025; exceeds 50% of total FY2025 revenue.","Net loss $3.5M vs $2.4M a year ago; cash $12.4M with runway into H2 2027.","Active commercial cancer centers grew to 16 from 8 at year-end 2025; target 36 by year-end 2026.","Phase III TIGeR-PaC enrollment at 106 of 114 patients (93%); full enrollment expected by June 2026.","FY 2026 revenue guidance reaffirmed at $3-4 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224080","json":"https://secwatch.observer/filing/0001193125-26-224080.json","markdown":"https://secwatch.observer/filing/0001193125-26-224080.md","text":"https://secwatch.observer/filing/0001193125-26-224080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000119312526224080/0001193125-26-224080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000119312526224080/rnxt-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:47:18.977542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fdbf20d8cbb05832397a0639dc718f918fa4da34","claim":"RenovoRx, Inc. reported the first quarter ended March 31, 2026 results: revenue $563,000.","evidence_excerpt":"herein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMPTM Therapy","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000119312526224080/0001193125-26-224080-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$563,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}